Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1140170

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases and Strokes: Females
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will respond to the recommendations in the report entitled Call for Action: Inquiry into heart attack and stroke, published by the all-party Parliamentary group on women’s health in July 2019; and if he will make a statement.
	tabling member constituency	Dewsbury
	tabling member printed	Paula Sherriff
	uin	279083
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>NHS England has acknowledged the recently published report and will be considering the content.</p><p>Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:54:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4426 label Biography information for Paula Sherriff

1140171

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases and Strokes: Females
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) outcomes, (b) early identification and (c) treatment of heart attack and stroke for women.
	tabling member constituency	Dewsbury
	tabling member printed	Paula Sherriff
	uin	279084
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.</p><p>In addition, addressing variations in outcomes from cardiovascular disease (CVD), such as heart attacks and stroke, is one of Public Health England’s (PHE) top priorities, and in February 2019, PHE announced new 10-year CVD ambitions for England, which are intended to complement the NHS Long Term Plan and are the first ever national ambitions to improve the detection and treatment of the major causes of CVD.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:48:22 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4426 label Biography information for Paula Sherriff

1140209

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions there have been between Vertex Pharmaceuticals and NHS England with on cystic fibrosis medicines.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	278928
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278929 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy

1140210

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will set a deadline for NHS England and Vertex Pharmaceuticals to come to an agreement to enable access to cystic fibrosis medicines produced by that company.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	278929
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278928 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy

1140227

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	5G: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what research his Department has conducted on the potential effect on public health of upgrading infrastructure to support 5G.
	tabling member constituency	Streatham
	tabling member printed	Chuka Umunna
	uin	279011
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Public Health England (PHE) advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The ICNIRP guidelines cover exposures arising from new 5G base stations, as well as from older technologies.</p><p>Many exposure measurements have been made at publicly accessible locations near to mobile phone base stations, and these have consistently been well within guidelines. It is possible that there may be a small increase in overall exposure to radio waves when 5G is added to an existing network or in a new area; however, the overall exposure is expected to remain low relative to guidelines and as such there should be no consequences for public health.</p><p> </p><p>PHE has published information about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p> </p><p>PHE continues to monitor the health-related evidence applicable to radio waves and is committed to updating its advice as required.</p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:52:28 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4128 label Biography information for Chuka Umunna

1140302

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rehabilitation Centres: County Durham
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of residential drug recovery services for women in County Durham.
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	278956
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The Government provides funding to local authorities for their public health responsibilities through a public health grant. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for residential drug treatment services taking account of their statutory duties.</p><p>Future funding for local authority public health functions will be a matter for the Spending Review.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278960 question first answered 23/07/2019 16:50:57 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3973 label Biography information for Grahame Morris

1140335

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rehabilitation Centres: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will increase the (a) funding for and (b) provision of residential drug treatment services.
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	278960
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The Government provides funding to local authorities for their public health responsibilities through a public health grant. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for residential drug treatment services taking account of their statutory duties.</p><p>Future funding for local authority public health functions will be a matter for the Spending Review.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278956 question first answered 23/07/2019 16:50:57 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3973 label Biography information for Grahame Morris

1140407

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle the overcharging of medicines to the NHS.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	279026
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department. For generic medicines, the Department encourages competition between suppliers to drive prices down. This generally works well but there are instances where there is no or not enough competition and prices appear unreasonably high. Section 262 of the National Health Service Act 2006 enables the Secretary of State to limit the price of any medicine not covered by the voluntary scheme for branded medicines. The Department is preparing a public consultation on the use of this power for generic medicines. The Health Service Products (Provision and Disclosure of Information) Regulations 2018 support the powers in the National Health Service Act 2006 by enabling the Secretary of State to require suppliers to provide information about their products including information about the cost of manufacturing those products.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279028 question first answered 23/07/2019 16:46:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1140408

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tetracosactide: Prices
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department is aware that synacthen has recently increased in cost from £2.70 per vial to £38 per vial; and if he will make a statement.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	279027
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The Department agreed the list price increase for Synacthen in March 2015.</p><p>The previous Pharmaceutical Price Regulation Scheme, the current 2019 Voluntary Scheme for Branded Medicines Pricing and Access and our statutory branded medicines pricing scheme all have detailed arrangements for how companies can request an increase to the National Health Service list price for a product.</p><p>Companies must comply with the rules of the relevant scheme when making a price increase request and all price increase requests must receive Departmental approval before they can take effect.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:53:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1140411

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department will use the Health Service Products (Provision and Disclosure of Information) Regulations 2018 to prevent price inflation of medicines.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	279028
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department. For generic medicines, the Department encourages competition between suppliers to drive prices down. This generally works well but there are instances where there is no or not enough competition and prices appear unreasonably high. Section 262 of the National Health Service Act 2006 enables the Secretary of State to limit the price of any medicine not covered by the voluntary scheme for branded medicines. The Department is preparing a public consultation on the use of this power for generic medicines. The Health Service Products (Provision and Disclosure of Information) Regulations 2018 support the powers in the National Health Service Act 2006 by enabling the Secretary of State to require suppliers to provide information about their products including information about the cost of manufacturing those products.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279026 question first answered 23/07/2019 16:46:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris